PT

Palvella Therapeutics, Inc.

PVLA·NASDAQ

$115.42

+10%
HealthcareBiotechnology

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.37B
EPS-3.7100
P/E Ratio-31.11
Earnings Date08/13/2026

pvla

Shares Outstanding

Last Annual Value

11.25M

3-Year CAGR

130%

5-Year CAGR

75%

10-Year CAGR

32%

PT

Palvella Therapeutics, Inc. Competitors Analysis of shares-outstanding

PVLA · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
11.25M
107.0%69.4%N/A 
59.60M
11.8%7.5%N/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
133.94M
29.5%33.2%N/A
87.68M
6.2%5.7%16.7%
SVRA logo
Savara Inc.
NASDAQ:SVRA
222.39M
10.4%10.7%52.1%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
76.00M
14.1%58.2%65.4%
98.57M
1.2%27.8%N/A
191.60M
4.9%12.5%13.7%
73.25M
23.5%20.6%36.9%
PT

Palvella Therapeutics, Inc. Fair Value Envelope

PVLA · NASDAQ

Our analysis suggests that PVLA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $115.42, this represents a potential HIDDEN relative to our calculated worth for Palvella Therapeutics, Inc..

Intrinsic Value
Current Price: $115.42